Insider Transactions in Q4 2023 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2023
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
251
+0.32%
|
$17,821
$71.62 P/Share
|
|
Dec 31
2023
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
76
+0.78%
|
$5,396
$71.62 P/Share
|
|
Dec 13
2023
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,262
-100.0%
|
$1,382,030
$65.0 P/Share
|
|
Nov 13
2023
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-58.93%
|
$2,650,000
$53.69 P/Share
|
|
Nov 13
2023
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+45.53%
|
$700,000
$14.1 P/Share
|
|
Nov 06
2023
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
42,393
-35.8%
|
$2,331,615
$55.5 P/Share
|
|
Nov 06
2023
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,754
+27.07%
|
$615,342
$23.94 P/Share
|